All In MedTech

Device Trial Radar · NCT00131326

A Study of the Safety and Efficacy of Synvisc and Depo-Medrol in Patients With Osteoarthritis of the Hip

Last checked: Nov 20, 2026Latest source record: Jul 31, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

Not stated

Start

Nov 2003

Primary completion

Not stated

Study completion Apr 2006

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanyNot on our public-company list
Sponsor type
Industry
First posted
Aug 18, 2005

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a clinical study to investigate the safety and efficacy of Synvisc and Depo-Medrol in treating patients with osteoarthritis (OA) of the hip.

Conditions

  • Osteoarthritis, Hip
  • Musculoskeletal Diseases

Interventions

  • Synvisc (hylan G-F 20)Device

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pain relief

Locations

32 sites in 1 country. Site status is shown where the registry gives one.

  • Alabama Clinical Therapeutics

    Birmingham, Alabama

  • John Higginbotham, MD Sports Medicine

    Huntsville, Alabama

  • Affiliated Orthopedic Specialists

    Scottsdale, Arizona

29 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.